DR REDDYS LABORATORIES LTD business relationships
Companies named in DR REDDYS LABORATORIES LTD’s 20-F filed 2026-05-29, and public companies whose annual reports name DR REDDYS LABORATORIES LTD. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in DR REDDYS LABORATORIES LTD’s annual report 4
“accounted for 48.3% of our retail sales in Russia for the 12 months ended March 31, 2026, according to IQVIA data.” SEC filing
“A key priority was accelerating the growth of our e‑commerce-only brand, HealthCareAisle®, driven by share expansion in core products and the launch of multiple new offerings on the Amazon marketplace.” SEC filing
“primarily through development and commercialization partnerships, , such as our 2024 partnership with Alvotech for the commercialization of a biosimilar candidate to Prolia® and Xgeva® (denosumab) in the United States and Europe, and our 2025 partnership with Shanghai Henlius Biotech, Inc. for the c...” SEC filing
“1,266 (U.S.$ 15 ) as a milestone payment receivable upon U.S. FDA approval of DFD 29, in accordance with the license and collaboration agreement dated June 29, 2021 with Journey Medical Corporation.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.